What Qlife does

Qlife Holding AB (Nasdaq First North Stockholm: QLIFE) is a Swedish-incorporated medical technology company that develops and markets the Egoo.Health platform — a modular, decentralized blood biomarker testing system consisting of the Egoo Q300 portable reader, swap-in test cartridges (HbA1c for diabetes management, PHE for phenylketonuria monitoring, hormone panels for women's health), and the Egoo.AI software module that delivers text-based personalized health insights to patients and clinicians. The platform is designed to deliver clinical-grade precision outside central laboratories, with the HbA1c test achieving a coefficient of variation below 3% and the PHE test demonstrating high concordance with Dry Blood Spot reference methods in the Birmingham Women's and Children's NHS Foundation Trust clinical trial.

Qlife operates through its wholly-owned Danish subsidiary Egoo.Health ApS and serves three primary customer segments: healthcare providers and institutions (hospitals, NHS trusts), pharmaceutical and IVD companies (via feasibility and licensing deals), and pharmacies and retail health providers (via a Nordic pilot). The business model is multi-stream and pre-commercial at scale: direct sales of Egoo hardware and consumable cartridges, a 20% royalty on net sales of Egoo products in China where Hipro Biotechnology owns manufacturing, regulatory, and commercialization, exclusive EU/US distribution rights for Hipro's FDA-approved HbA1c test under a 20-year agreement, and non-dilutive feasibility study funding from global pharma partners. Reported revenue remains minimal — kSEK 21 in Q1 2026 against an EBITDA loss of kSEK -5,502 — consistent with a platform still in regulatory, clinical-validation, and partnership-build phases.

Name

Qlife

Legal name

Qlife Holding AB

Website

https://qlifeholding.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Qlife Holding AB (Nasdaq First North Stockholm: QLIFE) is a Swedish medical technology company that develops the Egoo.Health platform — modular point-of-care blood biomarker testing devices and cartridges (HbA1c, PHE, hormones) with AI-driven insights — serving hospitals, pharmacies, and pharmaceutical partners across Europe, the US, and China via Hipro Biotechnology.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics / Home Medical Devices

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management) (HLALAFAL)

akta.pro secondary industries

Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF) (HLACAFAA), AI/Analytics for RPM (Risk Stratification, Alerts, Predictive) (HLACAFAM), Remote Patient Monitoring (RPM) Platforms & Services (HLACAPAA), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF)

Keywords

• Home diagnostics
• Point-of-care testing
• Biomarker analysis
• Decentralized diagnostics
• Clinical blood testing

Headquarters

HQ city

Helsingborg

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Egoo Platform Product Sales: Direct sales of Egoo.Health testing devices and consumable cartridges to healthcare providers, pharmacies, and consumers for home biomarker testing. Revenue generated from hardware sales and recurring consumable revenue in markets where regulatory approvals are in place.
2. Licensing Royalties (China): Qlife receives a 20% royalty on net sales generated from Egoo products in China, where Hipro assumes full responsibility for development, regulatory approvals, manufacturing, and commercialization. This provides an asset-light revenue stream with no capital expenditure requirements.
3. Distribution Revenue (EU/US - Hipro Products): Exclusive right to sell and distribute Hipro Biotechnology's products (including FDA-approved HbA1c test) in EU and US markets under a 20-year commercial agreement with automatic renewal. Qlife markets and distributes Hipro products integrated with or alongside the Egoo platform.
4. Feasibility Study Funding: Fully funded feasibility agreements with global pharmaceutical companies to evaluate specific biomarker applications on the Egoo Health platform for therapeutic use cases. Funded entirely by the pharma partner, representing non-dilutive revenue for R&D activities.
5. Partnership and Licensing Deals: Revenue from co-development and licensing arrangements with global IVD and pharmaceutical partners. Includes potential milestone payments, development fees, and long-term supply agreements as partnerships progress from feasibility to commercialization.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Qlife develops and markets the Egoo.Health platform, a modular, decentralized blood biomarker testing system that enables clinical-grade diagnostics at home. The platform combines the portable Egoo Q300 analyzer with cartridge-based assays (HbA1c for diabetes management, PHE for phenylketonuria monitoring, and women's hormone panels) and AI-driven personalized insights delivered through device-to-cloud connectivity.

Product overview

Qlife develops and markets the Egoo.Health medical technology platform for clinical-grade home diagnostics. The platform architecture consists of the Egoo Q300 hardware device supporting multiple test cartridges/modules including the Egoo HbA1c (diabetes management), Egoo PHE System (phenylketonuria monitoring), Women's Health Platform (hormone testing), and the Egoo.AI module for AI-driven personalized insights. The modular platform enables decentralized biomarker testing at home with accuracy comparable to central laboratory testing.

Differentiator

Problem solved

Functional benefit

Brands

• Egoo.Health: Medical technology platform for clinical-grade home diagnostics enabling biomarker testing at home
• Egoo Phe system
• Egoo HbA1c
• Egoo.AI
• Women's Health platform
• Egoo Q300

Products and services

• Egoo.Health Platform Clinical-grade medical technology platform for accurate biomarker testing at home. Uses a modular system that measures and analyses patient blood samples, enabling decentralized diagnostics for healthcare providers, pharmacies, pharma partners, and consumers.
• Egoo Q300 Device Portable blood testing device with AI integration, device-to-cloud connectivity, and support for multiple biomarker cartridge tests. Designed for clinical-grade accuracy at home and in pharmacy settings.
• Egoo HbA1c Blood Test Home-use HbA1c test cartridge for diabetes management achieving best-in-class precision with coefficient of variation below 3%. FDA-approved for the US market via the Hipro partnership.
• Egoo PHE System Home testing system for Phenylketonuria (PKU) monitoring in children and adolescents. Validated through Birmingham Women's and Children's NHS Foundation Trust clinical trial; submitted for European IVDR regulatory approval.
• Women's Health Platform Hormone testing platform with AI-driven personalized insights focused on women's reproductive and hormonal health, enabling proactive self-managed health monitoring at home.
• Egoo.AI AI-driven personalized health insights module integrated into the Egoo Health platform, providing customized health recommendations and chronic disease management insights based on biomarker test results.

Quantifiable outcome

• HbA1c coefficient of variation below 3% — best-in-class precision for home-use diabetes testing
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Global Pharmaceutical Company (unnamed)coreStrategic or Co-development Partner · 1 June 2026Qlife entered a fully funded feasibility agreement with a global pharmaceutical company to evaluate a specific biomarker application on Egoo Health related to a therapeutic use case. The feasibility study is entirely funded by the pharma partner and is designed to answer technical and integration questions required to move into a long-term development and supply collaboration. The partner remains undisclosed.
• Hipro Biotechnology Co., Ltd.coreStrategic or Co-development Partner · 16 December 2025Exclusive 20-year commercial agreement (with automatic renewal options) granting Qlife exclusive rights to distribute Hipro's products in the EU and US markets. Hipro has FDA approval for its HbA1c test (November 2024). The agreement includes integration of Hipro's FDA-approved HbA1c test with Qlife's Egoo platform, aiming to develop decentralized healthcare solutions. Separately, Qlife and Hipro pursued a reverse takeover (Nasdaq rejected the 'Red Chip' structure in November 2025; alternative structures being explored; LOI extended to December 31, 2026).
• Beijing Tsinghua Changgung HospitalminorStrategic or Co-development Partner · 12 December 2025Collaboration led by Hipro Biotechnology in China for an AI-driven personalized diabetes management project. Egoo Health blood testing platform is used for chronic disease management of diabetes and MASLD (metabolic dysfunction-associated steatotic liver disease). The project focuses on proactive healthcare using home testing and personalized health management.
• Birmingham Women's and Children's NHS Foundation TrustcoreStrategic or Co-development Partner · 5 November 2025Clinical validation partnership for the Egoo PHE testing system in children and adolescents with Phenylketonuria (PKU). The Birmingham study demonstrated high concordance between Egoo PHE Test results and Dry Blood Spot (DBS) reference methods. Results published in a peer-reviewed journal as a key milestone toward CE-mark submission and market launch.
• Hipro Biotechnology Co., Ltd. (Reverse Takeover)coreStrategic or Co-development Partner · 5 June 2025Qlife and Hipro entered a non-binding Letter of Intent for a reverse takeover (announced June 2025). Nasdaq Stockholm AB rejected the initially contemplated 'Red Chip' structure in November 2025. LOI was extended to December 31, 2026 while alternative transaction structures are pursued. This would combine Qlife (listed shell) with Hipro's manufacturing and regulatory infrastructure.
• Hipro Biotechnology Co., Ltd. (China Operations)coreTechnology or Integration · 13 March 2025Hipro assumes full responsibility for product development, regulatory submissions, manufacturing, and commercialization of Egoo in China. Qlife receives a 20% royalty on net sales generated from Egoo in China. Hipro has already implemented AI integration and user experience upgrades to the Egoo Q300 and plans to develop connectivity features enabling device-to-hospital communication. Strong interest from local hospitals in China is accelerating the process.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Abbott: Abbott's diagnostics division (FreeStyle Libre for glucose monitoring, i-STAT for point-of-care) directly competes with Qlife in clinical-grade home and point-of-care biomarker testing, targeting the same chronic disease management customers with established FDA-cleared products.
• Sinocare: Sinocare (including its PTS Diagnostics acquisition) is a direct competitor in point-of-care blood testing and consumer glucose monitoring, offering similar cartridge-based diagnostics and competing for pharmacy and home-use channels globally.
• i-SENS: i-SENS (Caresens brand) is a Korean point-of-care and home diagnostics company producing blood glucose and HbA1c monitoring systems, directly comparable to Qlife's Egoo HbA1c cartridge-based platform in clinical accuracy and target use cases.
• Trinity Biotech: Trinity Biotech develops point-of-care and clinical laboratory diagnostic tests, including HbA1c measurement, and competes in similar hospital and decentralized testing channels as Qlife's Egoo platform.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is a global IVD leader with extensive central lab and point-of-care offerings (cobas, Accu-Chek), competing broadly with Qlife across hospital, pharmacy, and home testing channels and serving as a benchmark for IVDR/FDA regulatory execution.
• Siemens Healthineers: Siemens Healthineers operates a broad IVD portfolio including the Atellica and DCA Vantage point-of-care HbA1c analyzer, making it a broad incumbent competitor in decentralized hospital and clinic testing markets where Qlife is seeking adoption.
• Bio-Rad Laboratories: Bio-Rad is a diversified diagnostics and life science company with clinical diagnostics products including HbA1c testing, providing a broader competitive context in regulated IVD markets that Qlife's Egoo platform targets.
• QuidelOrtho: QuidelOrtho is a broad diagnostics company with point-of-care and laboratory testing products, overlapping with Qlife's decentralized testing strategy across hospitals, clinics, and pharmacy channels.

Emerging players

• Biofourmis: Biofourmis is a remote patient monitoring and virtual care platform focused on chronic disease management using biosensors and AI, comparable to Qlife's hospital-at-home and AI-driven personalized health ambitions for chronic disease monitoring.
• Hinge Health: Hinge Health applies AI-driven digital care to chronic conditions and is comparable to Qlife's AI-enabled personalized health management strategy, though focused on musculoskeletal conditions rather than blood biomarkers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/28967666

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qlife